Findings

What do systematic reviews say?

3 questions · 3 findings · 1 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 2 · 66.7%Low 1 · 33.3%Moderate 0 · 0%High 0 · 0%

Mma Bana: AZT/3TC/LPV‐r vs AZT/3TC/ABC

Prematurity · HIV‐Infected Pregnant Women With CD4 Counts >200 cells/mm3

Mma Bana: AZT/3TC/LPV‐r may leads to higher prematurity compared with AZT/3TC/ABC (low certainty).

1 finding from 1 review

Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women 2010 · Cochrane Headline outcomes only
RR 1.52 [1.07, 2.17]
1 study · 553 participants
Low

Bae: AZT/3TC/NVP vs AZT (+/‐ single dose NVP)

Prematurity · HIV‐infected pregnant women with CD4 Counts <200 cells/mm31

It is very uncertain whether bae: AZT/3TC/NVP changes prematurity compared with AZT (+/‐ single dose NVP) (very low certainty).

1 finding from 1 review

Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women 2010 · Cochrane Headline outcomes only
RR 0.56 [0.21, 1.5]
1 study · 178 participants
Very low

Kesho Bora: AZT/3TC/LPV‐r vs Short‐Course AZT (intrapartum AZT/3TC/sd‐NVP)

Prematurity · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3

It is very uncertain whether kesho Bora: AZT/3TC/LPV‐r changes prematurity compared with short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) (very low certainty).

1 finding from 1 review

Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women 2010 · Cochrane Headline outcomes only
RR 1.23 [0.85, 1.79]
1 study · 805 participants
Very low